Department of Endoscopy and Laser, National Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ultrasound Med Biol. 2011 Dec;37(12):1993-9. doi: 10.1016/j.ultrasmedbio.2011.08.011. Epub 2011 Oct 27.
Nonsurgical therapies have become treatment options for hepatocellular carcinoma (HCC). This study was to evaluate the efficacy and complications of high-intensity focused ultrasound (HIFU) treatment for patients with HCC. Between May 2001 and May 2005, 145 patients with HCC were enrolled for treatments using a HIFU tumor therapeutic system. Clinical symptoms, hepatic functions and values of serum α-fetoprotein (AFP) were tested before and after HIFU treatment. The changes in computerized tomography (CT) and magnetic resonance imaging (MRI), complications and survival time after HIFU were also obtained for further analysis. Symptoms improved or pain was relieved in 84.8% of the 145 patients and the rate of serum AFP decrease was 71.7%. The size of the target tumor shrank by various degrees. The 2-year survival rate was 80% in patients with stage Ib HCC, 51.4% in stage IIa and 46.5% in stage IIIa. During HIFU treatment, complications included body temperature increase and abnormal cardiac rhythm. After HIFU procedures, there were skin burns of different grades. In conclusion, HIFU is safe and effective for patients with hepatocellular carcinoma; HIFU can improve the survival quality of patients with HCC.
非手术治疗已成为肝细胞癌（HCC）的治疗选择。本研究旨在评估高强度聚焦超声（HIFU）治疗 HCC 患者的疗效和并发症。2001 年 5 月至 2005 年 5 月，145 例 HCC 患者采用 HIFU 肿瘤治疗系统进行治疗。HIFU 治疗前后检测临床症状、肝功能和血清甲胎蛋白（AFP）值。对 HIFU 后 CT 和 MRI 的变化、并发症和生存时间进行了进一步分析。145 例患者中 84.8%的症状改善或疼痛缓解，血清 AFP 下降率为 71.7%。靶肿瘤的大小有不同程度的缩小。Ib 期 HCC 患者的 2 年生存率为 80%，IIa 期为 51.4%，IIIa 期为 46.5%。在 HIFU 治疗过程中，并发症包括体温升高和心律失常。HIFU 术后出现不同程度的皮肤灼伤。总之，HIFU 治疗肝细胞癌安全有效；HIFU 可提高 HCC 患者的生存质量。
